Skip to main navigation Skip to search Skip to main content

Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell disorders that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). This study examines the driver mutations among patients with MPNs in Kuwait. Patients and Methods: This study was a retrospective review of 942 MPN cases with a driver mutation from July 2007 to June 2019 to examine their demographic, clinical, and laboratory attributes. Results: The annual incidence of MPNs is 1.6 per 100,000 persons, and ET is the most common subtype. The median age of our cohort was 55 years, and the patients were predominantly male. We found that the most frequent gene mutation of MPNs in our cohort was the JAK2V617F mutation, which was present in 90% of cases, followed by the CALR exon 9, MPLW515L/K, and JAK2 exon 12 mutations. In our cohort, thrombotic events were observed in 18.7% of cases. Conclusion: Although Philadelphia-negative MPNs are rare hematologic malignancies, thrombosis is a relatively common initial presentation. The JAK2V617F mutation was the driver mutation in the majority of patients with MPN.

Original languageEnglish
Pages (from-to)483-488
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume21
Issue number7
DOIs
StatePublished - Jul 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Essential thrombocythemia
  • Kuwait
  • Myelofibrosis
  • Polycythemia vera
  • Thrombosis

Funding Agency

  • Kuwait Foundation for the Advancement of Sciences

Fingerprint

Dive into the research topics of 'Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms'. Together they form a unique fingerprint.

Cite this